A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Bristol-Myers Squibb (BMS)

Status and phase

Enrolling

Phase 2

Conditions

Carcinoma, Non-Small-Cell Lung

Treatments

Drug: MORAb-202

Study type

Interventional

Funder types

Industry

Identifiers

NCT05577715

CA116-003

MORAb-202-G000-203 (Other Identifier)

2022-000131-23 (EudraCT Number)

Details and patient eligibility

About

The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically or cytologically documented metastatic NSCLC AC (as defined by the 8th International Association for the Study of Lung Cancer Classification).
Measurable target disease assessed by the investigator according to RECIST 1.1.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

Exclusion criteria

NSCLC histologies other than AC (ie, squamous cell carcinoma, large cell carcinoma).
Significant third-space fluid retention (eg, ascites or pleural effusion) that requires repeated drainage.
Prior pneumonectomy. Prior lobectomy and segmentectomy are allowed > 12 months before treatment.
Recent chest radiotherapy. Participants with chest or chest wall radiation may be permitted if chest radiation is documented > 6 months before starting study treatment.

Other protocol-defined inclusion/exclusion criteria apply.